Martin Behe received his PhD in anorganic chemistry at the University of Basel. He worked at the University Hospitals in Göttingen, Marburg and Freiburg in Germany where he established a group for peptide-based radiopharmaceuticals and its production. Since 2011, Martin Behe leads the Pharmacology group at PSI, where the Araris Linker Technology took its first steps. He has an extensive background in peptide chemistry, peptide labelling and conjugation as well and critically contributed to development of radio-labelled compounds that are used in the clinic.
Current role
Co-founder & Scientific Advisor at Atalanta Therapeutics
Co-Founder & Scientific Advisor at Scribe Therapeutics
Co-Founder & Scientific Advisor at InterVenn Biosciences
Co-Founder & Scientific Advisor at Design Therapeutics
Co-Founder & Scientific Advisor at TwinStrand Biosciences